TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01209728

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo/ethanol (blinded)
Description: Elderly participants, including primary insomnia patients and healthy subjects will be administered i.v. ethanol or placebo in a blinded manner
Study: NCT00107783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitisinone (NTBC)
Description: Treatment
Study: NCT04615897

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: new tecnology intervention
Description: The intervention consists of 16 sessions, performed with a frequency of twice a week, the final evaluation was made within three days after the end of the last treatment session. It is used for the motor task, the Fishing Under Zero exercise, included within the balance modality and the so-called Step Plus located in the aerobic exercise folder. Each subject carried out the training taking into account the following methodology: 3 cycles of the Fishing under zero exercise, one cycle of the Step Plus exercise and 3 cycles of the Fishing under zero exercise, the approximate duration of the task being about 30 minutes.
Study: NCT01114152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9742
Description: IV Formulation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV Formulation
Study: NCT02187705

Intervention type: DRUG
Intervention: Telmisartan tablets
Description: All patients were treated with different doses of telmisartan for 14 days

Intervention type: DRUG
Intervention: Telmisartan tablets
Description: All patients were treated with different doses of telmisartan for 14 days

Intervention type: DRUG
Intervention: Telmisartan tablets
Description: All patients were treated with different doses of telmisartan for 14 days
Study: NCT00641303

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupuncture therapy
Description: Given weekly for 8 sessions

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: sham intervention
Description: Given weekly for 8 sessions
Study: NCT03897504

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: feminizing genitoplasty using inner surface of the prepuce as pedicled tubularized flap
Description: the prepuce of the females with congenital adrenal hyperplasia will be tubularized and used as pedicled flap in creating the new vagina, the urethra will be completed with the urogenital sinus, no mobilization either partial or complete urogenital mobilization will be needed in cases with low and intermediate confluence level (less than 30 mm), in case with high confluence (more than 30 mm) laparoscopic vaginal pullthrough will be attempted first then the same previously described technique will be applied, the depth of the confluence will be determined before starting surgery by doing genitograph under general anaesthesia, stent will be kept in the new vagina for 5 days and further scheduled calibrations and dilatations will be applied regularly with paying attention to urinary complications like incontinence and urethrovaginal fistula by doing urodynamics and micturating cystourethrogram if there is a complain.
Study: NCT01051466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: 60 milligrams (mg) administered orally daily for 8 weeks then 60-120 mg if non remitter or 60 mg if remitter for 4 additional weeks
Study: NCT02186431

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: senofilcon A

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A
Study: NCT03209349

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Air Insufflation Sigmoidoscopy
Description: See arm description.
Study: NCT03486938

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGB101 220 mg tablet
Description: 220 mg AGB101 active compound
Study: NCT01366196

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will first receive two capsules of the placebo drug (with no active ingredients per dose) one hour before surgery. Patients will continue taking two capsules per day until POD 14.
Study: NCT01895257

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HAI-90Y radioembolization (SIR-spheres injection)
Description: Patients randomised to receive the combination of SIR-Spheres microspheres plus systemic chemotherapy LV5FU2 need to be assessed in order to determine their suitability for SIRT.~1. Hepatic Angiogram~2. Liver-Lung Break-Through Nuclear Scan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: systemic chemotherapy LV5FU2
Description: Systemic chemotherapy with modified LV5FU2 will be administered according to the following regimen.~Cycle 1 onwards:~Day 1 Hour 0: Leucovorin L (levoleucovorin) 200 mg/m2 (or folinic acid 400 mg/m²) in 250 ml glucose 5%, 2-hour IV infusion Hour + 2: 5-FU bolus 400 mg/m2, IV bolus Hour + 2: 5-FU continuous infusion 2400 mg/m2, 46-hour cont. IV infusion Day 14 End of cycle. To be repeated every 14 days until evidence of treatment failure.
Study: NCT03023059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbidopa-Levodopa, 25 Mg-100 Mg Oral Tablet
Description: See Arm description
Study: NCT00598013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: The pioglitazone treatment group received 30mg pioglitazone at 2 weeks after renal transplantation for 12 months.
Study: NCT03278197

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interviews
Description: Interviews with patients, physicians and general practitioners (GPs) to define patients' decisional needs.

Intervention type: OTHER
Group type: OTHER
Intervention: Interviews
Description: Interviews with patients, physicians and general practitioners (GPs) to define patients' decisional needs.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatmentchoice Decisional Tool
Description: Patients and physicians navigate through Treatmentchoice Decisional Tool and think aloud while running the tool
Study: NCT03974360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 334
Description: 100 subjects with persistent post-traumatic headache will be allocated to receive monthly subcutaneous injections of 140 mg erenumab at three time points (week 0, week 4, week 8)
Study: NCT02076633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L19IL2+L19TNF
Description: Patients will be treated with intratumoral injections of 10 MioIU L19IL2 and 312μg L19TNF once weekly for up to 4 weeks.
Study: NCT03830242

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: <Sup>18<Sup>F-FDG PET/CT dynamic scan
Description: The purpose of this study is to carry out \<Sup\>18\<Sup\>F-FDG PET/CT dynamic scans and Pathological examination of metastatic central lymph nodes in newly diagnosed patients with papillary thyroid cancer, and to compare imaging findings, genomics, and pathology at the same time. The intrinsic relationship between tissue characteristics and the diagnostic value of \<Sup\>18\<Sup\>F-FDG PET/CT dynamic imaging in metastatic central lymph nodes with papillary thyroid cancer are discussed.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: B-ultrasonography
Description: The purpose of this study is to carry out \<Sup\>18\<Sup\>F-FDG PET/CT dynamic scans and Pathological examination of metastatic central lymph nodes in newly diagnosed patients with papillary thyroid cancer, and to compare imaging findings of B-ultrasonography , genomics, and pathology at the same time. The intrinsic relationship between tissue characteristics and the diagnostic value of \<Sup\>18\<Sup\>F-FDG PET/CT dynamic imaging in metastatic central lymph nodes with papillary thyroid cancer are discussed.
Study: NCT05014217

Intervention type: BEHAVIORAL
Intervention: Mentalization-based Treatment
Description: An empirically-validated intervention for personality disorders based on the attachment theory and on knowledge from developmental psychology and cognitive neuroscience (Bateman and Fonagy, 2004). Patients assist psychoeducative group meetings beforehand, along with a pretreatment of four to six individual meetings (over four to eight weeks), followed by bi-weekly individual follow-ups and weekly group follow-ups. The treatment lasts two years. Patients have an assessment meeting with their individual therapist and one of the group therapists at the end of each session. Psychiatric follow-up appointments are on an as-needed basis and every patient has a treatment contract with specific and measurable treatment objectives.

Intervention type: BEHAVIORAL
Intervention: Dialectical Behavior Therapy-inspired Treatment
Description: A psychotherapy developed by M. Linehan for patients with borderline personality disorder that combines cognitive behavioral therapy techniques (emotional regulation, practical exercises) with Buddhist meditation principles (stress tolerance, acceptance, open-mindedness) (Linehan, M. M. \& Dimeff, L., 2001). As opposed to Linehan's model, individual meetings are bi-weekly, no emergency phone service is offered, the mindful meditation module is reorganized into life habits modules, and every module includes mindfulness exercises. Patients assist psychoeducative group meetings beforehand, along with a pre-treatment of 4-6 individual meetings (over 4-8 weeks), followed by bi-weekly individual follow-ups and weekly group follow-ups. The treatment lasts one year, but can be extended to two years for eligible patients who are interested. Psychiatric follow-up appointments are on an as-needed basis. Every every patient has a treatment contract with specific and measurable treatment objectives.
Study: NCT00072657

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: The CBT intervention will have three phases: 1) education on the nature of the adjustment process in chronic illness, 2) coping skill development, and 3) generalization and application of skills to everyday situations. Participants in the CBT group will attend 12 weekly group sessions of about 2 hours each.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi Chih
Description: Participants in the TCC group will learn to perform 18 movements under the guidance of an expert TCC teacher. TCC participants will have 50- to 60-minute biweekly sessions during the 12-week study.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education Seminar
Description: Control group participants will attend weekly group educational sessions; these sessions will provide general knowledge about arthritis health and illness, and they will include lectures, demonstrations, and question-and-answer sessions with experts in rheumatology, sleep science, and behavioral medicine.
Study: NCT00547196

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study: NCT03278197

Intervention type: OTHER
Group type: OTHER
Intervention: Treatmentchoice Decisional Tool
Description: Patients and physicians navigate through Treatmentchoice Decisional Tool and think aloud while running the tool

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Patients and physicians fill out questionnaires on the usual care, Delphi study

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaires
Description: Patients and physicians fill out questionnaires on the usual care, Delphi study

Intervention type: OTHER
Group type: OTHER
Intervention: Interviews with stakeholders
Description: Interviews with stakeholders (patients, clinicians, nurses, GP's, patient organizations, insurance companies) to determine the barriers and facilitators to the implementation of shared decision making and the decision aid.
Study: NCT02887378

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hot clamps
Description: reusable hot biopsy forceps

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: normal clamps
Study: NCT01567059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tosedostat
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tosedostat
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine
Description: Given IV
Study: NCT00547196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine phosphate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine phosphate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine phosphate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine phosphate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: umbilical cord blood transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: umbilical cord blood transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: umbilical cord blood transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: umbilical cord blood transplantation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fractionated total body irradiation
Study: NCT04425356

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LifeXT Program
Description: The intervention involves participation in and completion of the 4-month LIFEXT program, including: A baseline 15-20 minute health assessment administered online, a 50 minute introductory, one-on-one telephonic coaching session, four 50 minute one-on-one telephonic coaching sessions, optional coaching session follow-up activities (such as videos, practice exercises, and reading materials), and a post-intervention 15-20 minute health assessment administered online.
Study: NCT03234673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus ointment
Description: 3 sessions of fractional CO2 laser one month apart Patients will start treatment Tarolimus ointment twice daily for 3 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: calcipotriol ointment
Description: 3 sessions of fractional CO2 laser one month apart Patients will start treatment Calcipotriol ointment twice daily for 3 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NB-UVB
Description: 3 sessions of fractional CO2 laser one month apart Patients will start treatment NB-UVB phototherapy twice weekly for 3 months
Study: NCT04202471

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chlorhexidine Cloth
Description: 2% chlorhexidine gluconate cloth
Study: NCT01092507

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Japanese encephalitis chimeric virus vaccine (JE-CV)
Description: 0.5 mL, Subcutaneous

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Japanese encephalitis live vaccine (SA14-14-2 vaccine) (CD.JEVAX®)
Description: 0.5 mL, Subcutaneous
Study: NCT02601599

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Description: The medical student will deliver a brief (approximately 15 minute) consultation with the patient that is based on principles of social cognitive theory and motivational interviewing. The goals of this consultation will be to enhance the patient's motivation and self-efficacy regarding quitting, and collaboratively elicit a plan to stay quit after discharge. Patients will be offered the opportunity to receive a consultation from the attending physician to determine eligibility for pharmacotherapy (via a chart sticker).~Each student will counsel 1-3 smokers each over the 8-month academic period, with student training and intervention staggered over this time. Students will also re-contact the smoker at 1-week post-discharge via telephone or personal follow-up, to provide further support.
Study: NCT03082482

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-help materials
Description: Self-help smoking cessation materials

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-help materials
Description: Self-help smoking cessation materials

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotine patch
Description: Participants who smoke \>10 cigarettes per day will receive 4 weeks of 21 mg, 2 weeks of 14 mg, and 2 weeks of 7 mg nicotine patches. Participants who smoke \<10 cigarettes per day will receive 6 weeks of 14 mg and 2 weeks of 7 mg nicotine patches.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nicotine patch
Description: Participants who smoke \>10 cigarettes per day will receive 4 weeks of 21 mg, 2 weeks of 14 mg, and 2 weeks of 7 mg nicotine patches. Participants who smoke \<10 cigarettes per day will receive 6 weeks of 14 mg and 2 weeks of 7 mg nicotine patches.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Counseling
Description: Proactive phone counseling with a Certified Tobacco Treatment Counselor

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smartphone-delivered automated treatment
Description: Tailored video clips, text and graphical messages delivered automatically each week to the participant.
Study: NCT03468985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT00326066

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Glaucoma Surgery
Description: Comparing the effect in reducing IOP with two Trabecular Bypass Microstents Versus none in patients undergoing cataract surgery, with early open angle glaucoma or ocular hypertension.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: cataract surgery only
Description: Subjects will undergo routine cataract surgery only (no stent implant).
Study: NCT01055522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm 1: L19IL2 + Dacarbazine
Description: RD of L19IL2 determined in phase IIa. Induction Phase A: Intravenous (IV) infusion of L19IL2 on days 1, 3 and 5 of each 21-day cycle over 60 minutes via automated device (perfusor), for four consecutive 21-day cycles.~Induction Phase B: Intravenous (IV) infusion of L19IL2 on days 1, 8 and 15 of each 21-day cycle over 60 minutes via automated device (perfusor), for four consecutive 21-day cycles.~Maintenance: Intravenous (IV) infusion of L19IL2 on days 1, 8 and 15 of each 21-day cycle over 60 minutes via automated device (perfusor), for a maximum of 1 year after start of treatment.~DTIC 1,000mg/m2 every three weeks until disease progression, unacceptable toxicity, withdrawal of consent, or one year from initiation of therapy, whichever occurs first

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arm 3: Dacarbazine
Description: Dacarbazine Dosage: 1,000 mg/m2 DTIC every three weeks until disease progression, unacceptable toxicity, withdrawal of consent, or for a maximum of 8 cycles, whichever occurs first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARM 2: L19IL2 + Dacarbazine
Description: RD of L19IL2 determined in phase IIa. Intravenous (IV) infusion of L19IL2 on days 1, 8 and 15 of each 21-day cycle over 60 minutes via automated device (perfusor), for for a maximum of 1 year after start of treatment.~DTIC 1,000mg/m2 every three weeks until disease progression, unacceptable toxicity, withdrawal of consent, or one year from initiation of therapy, whichever occurs first
Study: NCT02837068

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wheelchair handrail compensator
Description: Patients were treated by wheelchair handrail compensator for six times per week during the four-weeks treatment, with each treatment lasting at least 60 minutes, and follow up by eight weeks. The handrail compensator would help the paralysis upper limb kept the shoulder joint stretch forward, the elbow joint extend, the forearm in pronation, the wrist in flection and the fingers extend.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ordinary wheelchair
Description: Patients were treated by ordinary wheelchair for six times per week during the four-weeks treatment, with each treatment lasting at least 60 minutes, and follow up by eight weeks.The ordinary handrail could prevent the disable arm from sinking, but could not help the upper limp keep a normal position.